These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8915660)

  • 41. Cardiovascular risk factors in young Czech females with polycystic ovary syndrome.
    Vrbíková J; Cífková R; Jirkovská A; Lánská V; Platilová H; Zamrazil V; Stárka L
    Hum Reprod; 2003 May; 18(5):980-4. PubMed ID: 12721172
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The importance of lipid spectrum changes in women with polycystic ovary syndrome(PCOS).
    Sarapatkova H; Sarapatka J; Frysak Z
    Bratisl Lek Listy; 2014; 115(9):569-72. PubMed ID: 25318917
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study.
    Valkenburg O; Steegers-Theunissen RP; Smedts HP; Dallinga-Thie GM; Fauser BC; Westerveld EH; Laven JS
    J Clin Endocrinol Metab; 2008 Feb; 93(2):470-6. PubMed ID: 18056772
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome.
    Demirel F; Bideci A; Cinaz P; Camurdan MO; Biberoğlu G; Yesilkaya E; Hasanoğlu A
    Clin Endocrinol (Oxf); 2007 Jul; 67(1):129-34. PubMed ID: 17465999
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oxidised low-density lipoprotein concentration - early marker of an altered lipid metabolism in young women with PCOS.
    Macut D; Damjanovic S; Panidis D; Spanos N; Glisic B; Petakov M; Rousso D; Kourtis A; Bjekic J; Milic N
    Eur J Endocrinol; 2006 Jul; 155(1):131-6. PubMed ID: 16793959
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lipid and lipoprotein profile in women with polycystic ovary syndrome.
    Macut D; Panidis D; Glisić B; Spanos N; Petakov M; Bjekić J; Stanojlović O; Rousso D; Kourtis A; Bozić I; Damjanović S
    Can J Physiol Pharmacol; 2008 Apr; 86(4):199-204. PubMed ID: 18418429
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents.
    Silfen ME; Denburg MR; Manibo AM; Lobo RA; Jaffe R; Ferin M; Levine LS; Oberfield SE
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4682-8. PubMed ID: 14557441
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Women with polycystic ovary syndrome demonstrate worsening markers of cardiovascular risk over the short-term despite declining hyperandrogenaemia: Results of a longitudinal study with community controls.
    Huddleston HG; Quinn MM; Kao CN; Lenhart N; Rosen MP; Cedars MI
    Clin Endocrinol (Oxf); 2017 Dec; 87(6):775-782. PubMed ID: 29044581
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome.
    Guzelmeric K; Alkan N; Pirimoglu M; Unal O; Turan C
    Gynecol Endocrinol; 2007 Sep; 23(9):505-10. PubMed ID: 17852421
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Epidemiological survey of lipid levels and factors in Kazakan people over 30-year old in Fukang of Xinjiang].
    Liang DP; Yao XG; Li NF; Zhang DL; Guo YY; Lin L; Zhou L; Li WC; Yan ZT; Wang HM; Luo WL; Chang JH
    Zhonghua Yu Fang Yi Xue Za Zhi; 2011 May; 45(5):440-3. PubMed ID: 21756789
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical and hormonal features of women with polycystic ovary syndrome living in rural and urban areas.
    Katulski K; Czyzyk A; Podkowa N; Podfigurna-Stopa A; Ignaszak N; Paczkowska K; Slawek S; Szpurek D; Meczekalski B
    Ann Agric Environ Med; 2017 Sep; 24(3):522-526. PubMed ID: 28954502
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS).
    Atiomo WU; Fox R; Condon JE; Shaw S; Friend J; Prentice AG; Wilkin TJ
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):487-92. PubMed ID: 10762292
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Obesity, free testosterone, and cardiovascular risk factors in adolescents with polycystic ovary syndrome and regularly cycling adolescents.
    Glueck CJ; Morrison JA; Friedman LA; Goldenberg N; Stroop DM; Wang P
    Metabolism; 2006 Apr; 55(4):508-14. PubMed ID: 16546482
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
    Li X; Lin JF
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relation between C-reactive protein and body mass index in patients with polycystic ovarian syndrome.
    Moradi S; Mollabashi M; Kerman SR
    Gynecol Endocrinol; 2011 Jul; 27(7):480-5. PubMed ID: 20836727
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis.
    Wild RA; Rizzo M; Clifton S; Carmina E
    Fertil Steril; 2011 Mar; 95(3):1073-9.e1-11. PubMed ID: 21247558
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Retinol-binding protein in nonobese women with polycystic ovary syndrome.
    Lee JW; Im JA; Lee DC; Lee HR; Shim JY
    Clin Endocrinol (Oxf); 2008 May; 68(5):786-90. PubMed ID: 17986278
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome.
    Glintborg D; Altinok M; Mumm H; Buch K; Ravn P; Andersen M
    Hum Reprod; 2014 Aug; 29(8):1773-9. PubMed ID: 24903198
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Monocyte chemoattractant protein-1 and its correlation with lipoprotein in polycystic ovary syndrome].
    Hu WH; Qiao J; Zhao SY; Zhang XW; Li MZ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 38(5):487-91. PubMed ID: 17068620
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome.
    Rautio K; Tapanainen JS; Ruokonen A; Morin-Papunen LC
    Eur J Endocrinol; 2005 Feb; 152(2):269-75. PubMed ID: 15745936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.